Home › Therapeutic areas › Cardiovascular

Cardiovascular (23 companies · 23 conditions)

Conditions

Pulmonary Arterial Hypertension 4 Rare Pulmonary Hypertension Associated with Interstitial Lung Disease 4 Rare Atherosclerotic Cardiovascular Disease 3 Dilated Cardiomyopathy 3 Heart Failure 3 Hypertension 3 Arrhythmogenic Cardiomyopathy 2 Rare ATTR Amyloidosis 2 Rare Hypertrophic Cardiomyopathy 2 Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction 2 Rare Atrial Fibrillation 1 Catecholaminergic Polymorphic Ventricular Tachycardia 1 Rare Danon Disease 1 Rare Desmoplakin Cardiomyopathy 1 Rare Familial Chylomicronemia Syndrome 1 Rare Hereditary Hemorrhagic Telangiectasia 1 Rare Heterozygous Familial Hypercholesterolemia 1 Homozygous Familial Hypercholesterolemia 1 Rare Hyperlipidemia 1 Hypoplastic Left Heart Syndrome 1 Rare Myocarditis 1 Rare Paroxysmal Supraventricular Tachycardia 1 Pericarditis 1

Companies

Ticker	Company	Therapeutic areas	In Cardiovascular	Lead stage	Mkt cap	Programs
BIOA	BioAge Labs	CardiovascularOphthalmology	1	Phase 2	$245M	2
CRDL	Cardiol Therapeutics	Cardiovascular Rare	4	Phase 3	$121M	4
EWTX	Edgewise Therapeutics	Cardiovascular	3	Phase 2	$4.93B	3
EXEL	Exelixis	CardiovascularOncology	1	Approved	$17.0B	23
GOSS	Gossamer Bio	Cardiovascular Rare	4	NDA Submitted	—	4
INSM	Insmed	CardiovascularImmunology+3 Rare	2	Approved	$25.1B	15
NTLA	Intellia Therapeutics	CardiovascularImmunology Rare	2	NDA Submitted	$1.59B	3
IONS	Ionis Pharmaceuticals	CardiovascularHematology+5 Rare	5	Approved	$6.55B	29
LXEO	Lexeo Therapeutics	CardiovascularNeurology Rare	3	Phase 2	$237M	12
LQDA	Liquidia	CardiovascularImmunology+1 Rare	5	Approved	$3.97B	9
LGVN	Longeveron	CardiovascularMetabolic+1 Rare	2	Phase 2	$5.8M	4
MESO	Mesoblast	CardiovascularGI/Hepatology+2 Rare	1	Approved	$1.85B	5
MIST	Milestone Pharmaceuticals	Cardiovascular	2	Approved	$95.0M	2
MLYS	Mineralys Therapeutics	CardiovascularRenal+1	1	NDA Submitted	$1.36B	3
GLUE	Monte Rosa Therapeutics	CardiovascularDermatology+3 Rare	1	Phase 2	$903M	7
NAMS	NewAmsterdam Pharma	CardiovascularMetabolic+1	3	NDA Submitted	$2.27B	6
RVPH	Reviva Pharmaceuticals	CardiovascularDermatology+2 Rare	1	Phase 3	$4.8M	10
RCKT	Rocket Pharmaceuticals	CardiovascularImmunology Rare	3	Approved	$262M	4
SLDB	Solid Biosciences	CardiovascularNeurology Rare	4	Phase 3	$736M	6
TECX	Tectonic Therapeutic	Cardiovascular Rare	4	Phase 2	$412M	4
TENX	Tenax Therapeutics	Cardiovascular Rare	2	Phase 3	$77.0M	2
RARE	Ultragenyx Pharmaceutical	CardiovascularMetabolic+1 Rare	1	Approved	$1.57B	10
VNDA	Vanda Pharmaceuticals	CardiovascularDermatology+6 Rare	1	Approved	$231M	27